Bill > HR4605

This bill, known as the "End Prescription Drug Ads Now Act", aims to prohibit drug manufacturers from conducting direct-to-consumer (DTC) advertising for prescription medications across all media platforms. Specifically, the bill would amend the Federal Food, Drug, and Cosmetic Act to classify a drug as misbranded if its manufacturer has conducted any promotional communication targeting consumers within the past 30 days. These communications would include advertisements through television, radio, print media, digital platforms, and social media. The definition of direct-to-consumer advertising is broad, covering any promotional communication designed to market a prescription drug directly to the general public. The prohibition would apply to drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act, regardless of when the drug was originally approved. The amendment would take effect 30 days after the Act's enactment, effectively banning all prescription drug advertisements that target consumers through any media channel.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/4605/all-info